----item----
version: 1
id: {8C65F45F-C6D9-4F93-8B4E-D896BF896212}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/05/14/Denali launches with exGenentech management and $217mdeep pockets
parent: {C175FE23-2601-4F4F-B3CE-DA1791987470}
name: Denali launches with exGenentech management and $217mdeep pockets
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 6ca2d3af-f372-488d-a4af-e4efea35eea7

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 67

Denali launches with ex-Genentech management and $217m-deep pockets
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 65

Denali launches with exGenentech management and $217mdeep pockets
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1841

<p>Three ex-Genentech executives have secured whopping $217m to launch new company Denali Therapeutics focused on developing therapies for neurodegenerative diseases.</p><p>The creation of Denali is based on a collaboration between scientists, industry experts and investors, and is being driven by recent insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, which the founders believe offers an unprecedented opportunity to discover and develop effective medicines for Alzheimer's disease, Parkinson's disease, ALS and other neurodegenerative diseases.</p><p>Denali's co-founders are: </p><p>?Ryan Watts, acting CEO, CSO and board member of Denali, and former director of the department of neuroscience at Genentech </p><p>?Alexander Schuth, COO of Denali, former director and head of neuroscience partnering at Genentech </p><p>?Marc Tessier-Lavigne, chairman of the board of Denali, president of The Rockefeller University, and former CSO of Genentech. The launch of Denali coincides with his decision to step down from the board of directors at Pfizer.</p><p>The founding investors of Denali include Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund (represented by Crestline Investors). Additional investors include sovereign wealth funds, public mutual funds and private family offices, with significant reserves for additional future financing.</p><p>Robert Nelsen, a Denali board member and MD of ARCH Venture Partners, said, "Denali brings together independent experts in the industry, united in our dedication to successfully tackling this critical need. We recognize that the time is right for a serious, joint effort to effectively develop new therapies to treat neurodegenerative diseases."</p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 170

<p>Three ex-Genentech executives have secured whopping $217m to launch new company Denali Therapeutics focused on developing therapies for neurodegenerative diseases.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 65

Denali launches with exGenentech management and $217mdeep pockets
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150514T223255
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150514T223255
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150514T223255
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028723
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 67

Denali launches with ex-Genentech management and $217m-deep pockets
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{20E0B55E-5592-4DBF-A9D4-58B471A17E67}
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

358340
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042345Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

6ca2d3af-f372-488d-a4af-e4efea35eea7
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042345Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
